NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 139, Issue 1, Pages 171-176
Publisher
Wiley
Online
2016-02-18
DOI
10.1002/ijc.30047
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
- (2015) Hui Gao et al. NATURE MEDICINE
- Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
- (2015) Lecia V. Sequist et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma
- (2015) Emilio Bria et al. Oncotarget
- Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer
- (2015) Igor F. Tsigelny et al. Oncotarget
- Comprehensive characterization of chemotherapeutic efficacy on metastases in the established gastric neuroendocrine cancer patient derived xenograft model
- (2015) Jiahua Jiang et al. Oncotarget
- Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
- (2013) H. Yasuda et al. Science Translational Medicine
- Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
- (2013) A. O. Walter et al. Cancer Discovery
- A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy
- (2013) Lianhai Zhang et al. Scientific Reports
- Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naïve Asian NSCLC patients
- (2012) Mengmeng Yang et al. INTERNATIONAL JOURNAL OF CANCER
- Retrospective study of erlotinib in patients with advanced squamous lung cancer
- (2012) Jeng-Sen Tseng et al. LUNG CANCER
- Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
- (2011) Toni M. Brand et al. CANCER BIOLOGY & THERAPY
- EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
- (2011) Hiroyuki Yasuda et al. LANCET ONCOLOGY
- Promoter Methylation in Head and Neck Squamous Cell Carcinoma Cell Lines Is Significantly Different than Methylation in Primary Tumors and Xenografts
- (2011) Patrick T. Hennessey et al. PLoS One
- Establishment and Characterization of a Panel of Human Uveal Melanoma Xenografts Derived from Primary and/or Metastatic Tumors
- (2010) F. Nemati et al. CLINICAL CANCER RESEARCH
- Genome remodelling in a basal-like breast cancer metastasis and xenograft
- (2010) Li Ding et al. NATURE
- Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers
- (2010) KOH FURUGAKI et al. Oncology Letters
- Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts
- (2009) Fariba Némati et al. ANTI-CANCER DRUGS
- Establishment of Patient-Derived Non-Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers
- (2008) I. Fichtner et al. CLINICAL CANCER RESEARCH
- EGFR Antagonists in Cancer Treatment
- (2008) Fortunato Ciardiello et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation